Ending US Dependence on Chinese-Manufactured Pharmaceuticals

Ending US Dependence on Chinese-Manufactured Pharmaceuticals

China makes most generic drugs and therefore control the health of much of the world.

Wednesday, Senator Tom Cotton (R:AR) and Congressman Mike Gallagher (R:WI) introduced a bill to end US dependence on Chinese-manufactured pharmaceuticals after China threatened to cut America’s access to vital drugs.

The Chinese Communist Party has threatened to cut off America’s access to vital drugs in the midst of a pandemic caused by its own failures. It’s time to pull America’s supply chains for life-saving medicine out of China and make the CCP pay for contributing to this global emergency,” said Senator Cotton.

“The Chinese Communist Party’s outrageous threats to withhold lifesaving drugs from the US endangers public health and should open our eyes to our dangerous over-reliance on China in our medical supply chain,” said Mr. Gallagher. “This is a national security imperative that to many Americans, is a matter of life and death. It’s past time for us to develop an aggressive plan to move critical pharmaceutical supply chains away from China.

Specifically, their bill will do the following:

  1. Track active pharmaceutical ingredients through an FDA registry.
  2. Prohibit pharmaceutical purchases from China or products with active pharmaceutical ingredients (APIs) created in China.
  3. Create transparency in the supply chain by instituting a country of origin label of all imported drugs.
  4. Provide economic incentives for manufacturing drugs and medical equipment in the United States.

At the end of World War II, the United States was the dominant manufacturing country of the world, under President Trump, our current wartime President, it will be again.

Have a healthy day.

The following two tabs change content below.

Paul Ebeling

Paul A. Ebeling, polymath, excels in diverse fields of knowledge. Pattern Recognition Analyst in Equities, Commodities and Foreign Exchange and author of “The Red Roadmaster’s Technical Report” on the US Major Market Indices™, a highly regarded, weekly financial market letter, he is also a philosopher, issuing insights on a wide range of subjects to a following of over 250,000 cohorts. An international audience of opinion makers, business leaders, and global organizations recognizes Ebeling as an expert.

You must be logged in to post comments :  
CONNECT WITH